2013 Fiscal Year Final Research Report
Exhaustive study for aquisition of eary diagnostic or the anti-cancer drug sensitivity markers for lung cancer
| Project/Area Number |
23590414
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
SATO Yuichi 北里大学, 医療衛生学部, 教授 (30178793)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 肺癌 / 抗癌剤感受性予測 / 早期診断 / 単クローン性抗体 / 自己抗体 |
|---|
| Research Abstract |
Erom established monoclonal antibodies for lung cancder, I selected useful early sero-diagnostic markers. As a results, anti-CAXII antibody was reported as asero-diagnostic marker (PLOS ONE 7(3): e33952, 2012). In addition, I submitted that antiBSG and MHY9 antibodies were useful markeres for pathological diagnosis of lung cancer. Ant-IMMT antibody was established as a sensitivity prediction marker of the platinum.
By the analysis of tumor-associated autoantibodies, I reported antiHu-C, Hu-D autoantibodies were novel differential sero-diagnostic markers for small cell lung carcinoma from large cell neuroendocrine carcinoma (Int J Oncol 40: 1957-1962, 2012).Ant-Galectin-3 autoantibody was found as an anticancer drug sensitivity prediction marker. And, I reported methodology that aquisition of useful sero-diagnostic autoantibodies using the same patients' sera and tumor tissues (Biomed Res 35(2): 133-143, 2014.
|
